Here's what life science startups were named most promising at the recent Rice Alliance Texas Life Science Forum.. Getty Images

Houston hosted an annual meeting of the minds that included thoughtful discussions, presentations, panels, and startup pitches within the life science industry.

The Texas Life Science Forum, organized and hosted by the Rice Alliance and BioHouston, took place on November 6 at Rice University's Bioscience Research Collaborative. Throughout the day, over 50 life science startups pitched to the audience. At the end of the forum, 10 startups — most of which are based in Houston — were recognized as being the most promising.

Here's what life science startups you should be keeping an eye out for.

Abilitech Medical

abilitech

Photo via abilitechmedical.com

A St. Paul, Minnisota-based medical device company, Abilitech Medical develops assistive technology to Multiple sclerosis, Muscular Dystrophy, Parkinson's and stroke patients. The first product, Alibitech Assist, will be cleared by the FDA in 2020, with other devices to follow in 2022 and 2023.

AgilVax

agilvax

Photo via agilvax.com

Based in Albuquerque, New Mexico, AgilVax is a biopharmaceutical company that works with chemotherapy, checkpoint and KRAS inhibitors to fight various cancers. The company's AX09 is an immunotherapeutic that is headed for human clinical trials in 2020. Another product, M5, is a monoclonal antibody currently in preclinical trials.

Altoida

altoida

Photo via altoida.com

Altoida, based in Houston, has created a medical device that uses artificial intelligence and augmented reality to collect functional and cognitive data in patients to determine their risk Mild Cognitive Impairment from Alzheimer's Disease. The Altoida Neuro Motor Index has been cleared by the FDA and CE and detects cognitive decline with a 94 percent diagnostic accuracy six to 10 years ahead of the onset of symptoms.

ColubrisMX

Photo via Pexels

Houston-based ColubrisMX makes surgical robots specializing in minimally invasive and endoluminal surgeries. The company's team of engineers and surgeons works adjacent to the Texas Medical Center.

Cord Blood Plus

stem cell

Photo via Getty Images

Cord Blood Plus, based in Galveston, is working to commercialize its human umbilical cord blood stem cell technology. The company's primary mission is to use its research and treatment on breast cancer patients undergoing chemotherapy in order to prevent infections, speed up recovery, and shorten hospital stays.

CorInnova

CorInnova

Photo via CorInnova.com

Another Houston company, CorInnova is a medical device company that has developed a cardiac assist device to treat heart failure without many of the consequences from standard treatment. The device is able to self expand and gently compress the heart in sync with the heartbeat.

Mesogen

mesogen

Photo via Mesogen.com

Mesogen, which is based in The Woodlands, is in the business of using a patient's own cells to grow a human kidney for transplant. The tissue engineering technology allows for the creation of a kidney in less than a year with less risk of transplant rejection and a better quality of life over dialysis treatment.

Saranas

Courtesy of Saranas

Houston-based Saranas has created its Early Bird device to more quickly and more accurately detect bleeding in the human body. The company, which underwent successful clinical trials last year, recently received FDA clearance and launched the device in the United States.

Stream Biomedical

stream biomedical

Photo via streambiomedical.com

Stream Biomedical Inc. is tapping into a therapeutic protein that has proven to be neuroprotective and neuroreparative. The Houston company is aiming to apply the treatment in acute stroke cases and later for traumatic brain injury, Alzheimer's, and dementia cases.

VenoStent

Photo via venostent.com

Houston-based VenoStent has created a device that allows a successful stent implementation on the first try. VenoStent's SelfWrap is made from a shape-memory polymer that uses body heat to mold the stent into the vein-artery junction.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”